SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that it will continue its US coast-to-coast momentum with a collaboration agreement with the Skin and Cancer Reconstructive Surgery Center (“SCARS Center”) in California.
This partnership will help further introduce Nevisense to a broader US market. The Nevisense System is a first-of-its-kind AI-driven technology that uniquely addresses the complexities of point-of-care detection of the deadliest form of skin cancer by providing clinicians with advanced analysis of irregular moles during routine skin checks.
“Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes,” said Dr. Simon Madorsky, medical director and founder of the Skin Cancer and Reconstructive Surgery Center. Dr. Madorsky is also the CME Chair of the SCARS Foundation, dedicated to skin cancer research and physician education. “At SCARS Center, we are dedicated to providing our patients and physicians with the resources needed to understand, prevent, and cure skin cancers. We have long been at the forefront of innovation, and we look forward to furthering those capabilities with Nevisense. Early detection of skin cancers with advanced technology provides patients with the peace of mind they deserve during skin cancer checks,” said Dr. Madorsky.
“SciBase and the SCARS Center team are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes,” said Pia Renaudin, CEO of SciBase. “We are continuing to broaden SciBase’s presence throughout the US, to further increase patient access to point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable”.
